• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to protection against viral challenge

tetano

Editor, Senior Moderator
Sci Rep. 2018 Aug 7;8(1):11856. doi: 10.1038/s41598-018-30079-4.
[h=1]Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to protection against viral challenge.[/h] Kuenstling TE[SUP]1[/SUP], Sambol AR[SUP]1,[/SUP][SUP]2[/SUP], Hinrichs SH[SUP]1,[/SUP][SUP]2[/SUP], Larson MA[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Vaccination is the most effective intervention to prevent influenza and control the spread of the virus. Alternatives are needed to the traditional egg-based vaccine strategy for a more rapid response to new outbreaks. Two different hemagglutinin (HA) fragments (rHA1[SUB]1-326[/SUB] and rHA1[SUB]53-269[/SUB]) derived from influenza A virus subtype H1N1 were expressed in Escherichia coli and characterized by immunoblot, gel filtration, hemagglutination, and competitive binding assays. rHA1[SUB]1-326[/SUB] included neutralizing epitopes and the trimerization domain, whereas rHA1[SUB]53-269[/SUB] included only the head of HA with the neutralizing epitopes. Mice were immunized with rHA1[SUB]1-326[/SUB] or rHA1[SUB]53-269[/SUB], and sera were tested for the presence of neutralizing antibodies. Mice were then challenged with H1N1 and infection severity was monitored. rHA1[SUB]1-326[/SUB] trimerized, whereas rHA1[SUB]53-269[/SUB] was unable to form oligomers. Both rHA1[SUB]1-326[/SUB] and rHA1[SUB]53-269[/SUB] elicited the production of neutralizing antibodies, but only oligomerized rHA1[SUB]1-326[/SUB] protected against live virus challenges in mice. This study demonstrated that bacterially expressed HA was capable of folding properly and eliciting the production of neutralizing antibodies, and that HA oligomerization contributed to protection against viral challenge. Therefore, prokaryotic-derived vaccine platforms can provide antigenic and structural requirements for viral protection, as well as allow for the rapid and cost-effective incorporation of multiple antigens for broader protection.


PMID: 30087372 DOI: 10.1038/s41598-018-30079-4
Free full text
 
Back
Top Bottom